Vor Biopharma VOR Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 31.1×+12.9× | 18.2×+9.0× | 9.2×+5.7× | 3.5×-0.4× | 3.9×-1.3× | |
| Quick ratio | 31.1×+12.9× | 18.2×+9.0× | 9.2×+5.7× | 3.5×-0.4× | 3.9×-1.3× | |
| Cash ratio | 10.6×-5.2× | 15.8×+7.2× | 8.5×+5.3× | 3.2×+0.3× | 3×-1.4× | |
| Leverage | ||||||
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×— | —— | 0.3×+0.1× | |
| Per Share | ||||||
| Book value per share | -$3.50+79.0% | -$16.64+95.0% | -$333.07-2,671% | -$12.02-214% | $10.59+138% | |
| Valuation | ||||||
| Market capitalization | $784.61M+2,594% | $286.59M-14.2% | $333.92M+740% | $39.75M-55.6% | $89.58M-35.2% | |
| Enterprise value | $617.68M+5,866% | -$106.89M-161% | $176.52M— | —— | $70.32M-20.2% | |
| Free cash flow yield | -18.6%+316pp | -50.1%-6.8pp | -43.3%+244pp | -287%-175pp | -112.3%-40.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vor Biopharma's ratios come from?
- Every ratio is computed from Vor Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.